Catalent, Inc. (NYSE: CTLT) today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies.

Catalent, Inc. (NYSE: CTLT) and Paragon Bioservices, Inc. today announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.

Triphase Accelerator Corporation and Catalent today announced that Triphase Accelerator’s TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma, has been dosed in the first patient in a Phase 1 clinical trial.

Catalent Pharma Solutions today announced that two of its manufacturing experts will present at the INTERPHEX Conference and Exhibition, taking place at the Javits Center, New York City, on April 2-4, 2019.

The Catalent Applied Drug Delivery Institute today announced that it is to hold a one-day symposium entitled “Advances in Biologics Development and Delivery”.

Catalent Pharma Solutions today announced that two of its scientific experts will present at the International Society for Pharmaceutical Engineering (ISPE) Aseptic Conference.

Catalent Pharma Solutions today announced that Michael Sadick, Ph.D., Principal Scientist, Catalent Biologics, will present at the annual US Bioassay Conference of the BioPharmaceutical Emerging Best Practices Association (BEBPA).

Catalent Pharma Solutions today announced that Cornell Stamoran, Ph.D. will present at the 23rd annual Drug Delivery Partnerships (DDP) conference.

Catalent Pharma Solutions , today announced that one of its scientific experts will present at CASSS’s WCBP conference, the 23rd Symposium on the Interface of Regulatory & Analytical Sciences for Biotechnology Health Products, co-sponsored by the US Food and Drug Administration, at The Mayflower Hotel, Washington, D.C. on Jan. 29 – 31, 2019.